Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (NCT03261206)

🧪 Interventions in This Study

• 5-ASA Withdrawal (OTHER)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (46 Sites)

Showing the first 25 of 46 sites.

• University of Calgary — Calgary, Alberta
• University of Alberta — Edmonton, Alberta
• Dr. Jesse Siffledeen Professional Medical Corporation — Edmonton, Alberta
• (G.I.R.I.) GI Research Institute — Vancouver, British Columbia
• Discovery Clinical Services Ltd. — Victoria, British Columbia
• University of Manitoba - Health Sciences Centre — Winnipeg, Manitoba
• London Health Sciences Centre - University Hospital — London, Ontario
• Scott Shulman Medical Professional Corporation — North Bay, Ontario
• Taunton Surgical Center — Oshawa, Ontario
• Mount Sinai Hospital — Toronto, Ontario
• Dr. O. Tarabain Medicine Professional Corporation — Windsor, Ontario
• McGill University Healthcare — Montreal, Quebec
• IRCCS Policlinico San Donato — San Donato Milanese, Milan Italy
• Ospedale San Raffaele S.r.I. — Milan, Milan
• UOC Gastroenterologic UOS Malattie Infiammatorie Intestinali, Ospedali — Roma, Rome
• IRCCS De Bellis — Castellana Grotte, Via Turi
• Luigi Vanvitelli of Campania — Catania,
• Intituto Clinico Humanitas — Milan,
• Azienda Ospedale-Universita Padova — Padova,
• Campus Bio-Medico University of Rome — Roma,
• BYK - Kyiv — Kyiv,
• Danylo Halytsky Lviv National Medical University — Lviv,
• Odesa Regional Clinical Hospital — Odesa,
• Ternopil University Hospital — Ternopil,
• Warrington and Halton Hospitals NHS Foundation Trust — Warrington, Cheshire

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn Disease

• Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease — Lutherville, Maryland
• Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial — New Haven, Connecticut
• A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease — Portland, Oregon
• Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) — Ottawa, Ontario
• A Long-term Extension Study of Ustekinumab in Pediatric Participants — Atlanta, Georgia
• Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease — Atlanta, Georgia

Explore by condition: All Crohn Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.